Combined identification of LncRNA CCAT1 and SOX2OT in serum as an effective screening for non-small cell lung cancer.
Year: 2019
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Long non-coding RNAs (lncRNAs) CCAT1 and SOX2OT have been shown to play important regulatory roles in cancer biology. Tumor biomarkers need to be detectable in easily accessible body fluids, should be characterized by high specificity, sufficient sensitivity, and robustness against influencing factors. The aim of this study is to evaluate the clinical significance of serum CCAT1 and SOX2OT as a biomarker in the screening of NSCLC. RESULTS: CCAT1 and SOX2OT were shown to be detectable in the cellular fraction of peripheral human blood, showing serum levels of CCAT1 and SOX2OT were significantly increased of cancer patients as compared to cancer-free controls. The ROC curves illustrated strong separation between the NSCLC patients and control group, with an AUC of 0.846 (95% CI 0.766-0.926; P < 0.001) for CCAT1 and 0.787 (95% CI: 0.691-0.883; P < 0.001) for SOX2OT. However, the combination of SOX2OT and CCAT1 yielded an AUC of 0.894 (95% CI: 0.825-0.963; P < 0.001), which was significantly improved as compared to CCAT1 or SOX2OT alone. Moreover, the interaction between lncRNAs and some functional proteins, such as TTF1, p63, Ck7, K-ras, EGFR, may contribute to the tumorigenesis. CONCLUSION: Our results demonstrated that increased serum CCAT1 and SOX2OT could be used as a predictive biomarker for NSCLC screening, and that combination of CCAT1 and SOX2OT had a higher positive diagnostic efficiency of NSCLC than CCAT1 or SOX2OT alone.
Source: Europe PMC (PubMed Central)
Authors: Zhipeng Wang, Jian Li, Yan Wu, Hongbin Wang
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3010743517